DSM Venturing Invests In Tianjin GreenBio
This article was originally published in PharmAsia News
Holland DSM Venturing has completed its initial investment in China that involves a $20 million share in Tianjin Green Biosciences Ltd. Co. The fund will be used to build China's largest polyhydroxyalkanoate production in Tianjin Economic - Technological Development Area, with construction to begin in the second quarter of this year. Targeted for operation in the beginning of 2009, the facility has the capacity to output 10,000 tonnes of PHA annually. DSM chose to invest in PHA for its use in the production of environment-friendly products. The company revealed that it has allocated €200 million for venture capital before 2012 and China will be one of its key investment areas. (Click here for more - Chinese Language)
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.